Raise closed, search for fresh raises on Seedstage

Escondido, CA

Revolutionizing cancer treatment through AI-powered cell therapy development.

• Mission: AiCella is revolutionizing cancer treatment by leveraging AI and machine learning to optimize cancer cell therapies, particularly CAR-T therapies, to improve patient outcomes and streamline therapy development.  
• Technology: Their platform, Insights™, utilizes AI to analyze critical process parameters in cancer cell therapy production, enhancing the efficiency and effectiveness of treatments.  
• AI-Driven Approach: AiCella integrates AI with clinical and manufacturing data to predict patient responses, improve compliance with Good Manufacturing Practices (GMP), and support regulatory filings for clinical trials.  
• Innovation in Biotechnology: By focusing on personalized cancer treatment, AiCella aims to accelerate the transition from research to clinical application, making advanced therapies more accessible and affordable.  
• Market Expansion: AiCella is seeking funding to enhance its platform, grow its team, and expand its market presence, contributing to the broader goal of democratizing access to cutting-edge cancer treatments.  
• Collaboration: The company collaborates with pharmaceutical companies, biotech firms, and research institutions to refine and scale the development of personalized cancer therapies.

AiCella, Inc. is at the forefront of transforming cancer treatment through innovative AI and machine learning technologies, specifically in the realm of cancer cell therapies. The company aims to enhance the effectiveness, efficiency, and accessibility of these therapies by developing a comprehensive platform known as InsightsTM, which analyzes critical process parameters that influence patient outcomes.

By providing essential tools and support for cell therapy manufacturers, AiCella seeks to streamline the transition from research and development to clinical application, thereby accelerating the delivery of life-saving treatments. Their vision includes compliance with good manufacturing practices, verification of AI models, and support for investigational new drug applications, ensuring a robust framework for therapy development.

With a dedicated team of experts in biotechnology and immunology, AiCella is committed to addressing the complexities and costs associated with cell therapy production. The company is currently seeking funding to further enhance its platform, expand its team, and increase its market presence, ultimately striving to democratize access to advanced cancer treatments and make a meaningful impact on the lives of patients worldwide.

Company Info

Aicella Inc specializes in optimizing CAR-T therapy development using AI-driven tools and methodologies.

Aicella Inc is a biotechnology company focused on advancing CAR-T therapy development through innovative tools and methodologies. The company aims to address the increasing demand for personalized cancer treatments by providing solutions that streamline research and development processes, thereby improving patient outcomes. Central to Aicella’s offerings is the InsightsTM data dashboard, which integrates artificial intelligence and machine learning to analyze critical process parameters in relation to patient responses. This tool supports various aspects of process development, including compliance with Good Manufacturing Practices (GMP), the creation of standard operating procedures (SOPs), and assistance in regulatory filings for Investigational New Drug applications. Aicella collaborates with pharmaceutical companies, biotech firms, and research institutions to enhance the efficiency of CAR-T therapy development and aims to leverage AI to uncover insights that predict treatment success. The company is located in San Diego, California, within a prominent biotechnology hub, and is committed to fostering innovation in personalized medicine through advanced technology and data-driven analysis.